Arş. Gör. İVO GÖKMEN

1. Aggressive Paratesticular Spindle Cell Rhabdomyosarcoma in an Adult: A Rare Case and Review of Reported Adult Cases

BAYRAKÇI İ., Gökmen İ., Demirtaş E. M., Divriklioğlu D., AYDIN T. İ., HACIOĞLU M. B.

Clinical Genitourinary Cancer , cilt.24, sa.1, 2026 (SCI-Expanded, Scopus)

2. Medication Adherence in Women with Early-Stage Breast Cancer and Active Parenting Responsibilities: The Mediating Role of Parenting Stress and Spiritual Well-Being

Çakıcı V., Oğuz A., Can S., Kahveci G. B., Gür H. B., Akgül F., et al.

Medicina (Lithuania) , cilt.62, sa.2, 2026 (SCI-Expanded, Scopus)

3. Does toxicity of cyclin-dependent kinase 4/6 inhibitor predict treatment response in metastatic hormone-positive breast cancer patients?

Gulbagci B., Demirci A., Celebi A., Firat S. T., GÖKMEN İ., Ugurlu I., et al.

ONCOLOGY IN CLINICAL PRACTICE , 2025 (ESCI, Scopus) Sürdürülebilir Kalkınma

4. Characteristic features and prognostic factors in gastric cancer patients with bone metastases: multicenter experience

Hamdard J., BİLİCİ A., Sakin A., Kahraman S., Yasin A. I., Kalaci E., et al.

Journal of Chemotherapy , cilt.37, sa.3, ss.268-277, 2025 (SCI-Expanded, Scopus)

5. Gustave Roussy immune score as an independent prognostic factor for treatment response and survival in advanced renal cell carcinoma treated with nivolumab in second-line and beyond

ERDOĞAN B., Gökmen İ., ELPEN KODAZ Ç., KÜÇÜKARDA A., Divriklioğlu D., BAYRAKÇI İ., et al.

Frontiers in Oncology , cilt.15, 2025 (SCI-Expanded, Scopus)

6. Clinical Outcomes of CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer: A Multicenter Comparison of HER2-Low and HER2-Zero Subgroups

ÖZCAN E., GÖKMEN İ., AKGÜL F., Kahvecioglu F. A., Celebi A., KÖSTEK O., et al.

Breast Journal , cilt.2025, sa.1, 2025 (SCI-Expanded, Scopus)

7. The real-world outcomes of Lutetium-177 PSMA-617 radioligand therapy in metastatic castration-resistant prostate cancer: Turkish Oncology Group multicenter study

Almuradova E., Seyyar M., Arak H., Tamer F., KEFELİ U., Koca S., et al.

International Journal of Cancer , cilt.154, sa.4, ss.692-700, 2024 (SCI-Expanded, Scopus)

8. Prognostic value of the HALP score in metastatic castration-resistant prostate cancer: an analysis combined with time to castration resistance

Gökmen İ., Demir N., Peker P., Özcan E., Akgül F., BAYRAKÇI İ., et al.

Frontiers in Oncology , cilt.14, 2024 (SCI-Expanded, Scopus)

9. Pilomatrix Carcinoma with Pulmonary Metastasis

AKGÜL F., CAN N., TOPUZ C., GÖKMEN İ., ÖZCAN E., HACIOĞLU M. B., et al.

Journal of Oncological Science , cilt.10, sa.1, ss.69-72, 2024 (Scopus, TRDizin)

10. Comparison of Breast Graded Prognostic Assessment Scores in a Turkish Cohort of Patients with Brain Metastatic Breast Cancer

GÖKMEN İ., Demir N., Peker P., ÖZCAN E., AKGÜL F., BAYRAKÇI İ., et al.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.34, sa.4, ss.195-205, 2024 (SCI-Expanded, Scopus)

11. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Karacin C., Oksuzoglu B., Demirci A., Keskinkılıç M., Baytemür N. K., Yılmaz F., et al.

BMC Cancer , cilt.23, sa.1, 2023 (SCI-Expanded, Scopus)

12. Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

Gökmen İ., TAŞTEKİN E., Demir N., Özcan E., Akgül F., HACIOĞLU M. B., et al.

Current Issues in Molecular Biology , cilt.45, sa.10, ss.7803-7812, 2023 (SCI-Expanded, Scopus)

13. Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib

ERDOĞAN B., Ozcan E., Gokmen I., Gokyer A., KÜÇÜKARDA A., KÖSTEK O., et al.

Journal of Cancer Research and Therapeutics , cilt.19, sa.3, ss.762-767, 2023 (SCI-Expanded, Scopus)

14. An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea

CAKCAK İ. E., AYTİN Y. E., Sayin S., KÜÇÜKARDA A., GÖKYER A., GÖKMEN İ., et al.

Turkish Journal of Medical Sciences , cilt.53, sa.1, 2023 (SCI-Expanded, Scopus, TRDizin)

15. Real-life experience of patients with sarcomatoid renal cell carcinoma: a multicenter retrospective study

Almuradova E., Basoglu T., Nayir E., BAYRAM E., PAYDAŞ S., GÖKMEN İ., et al.

NEOPLASMA , cilt.70, sa.1, ss.158-165, 2023 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

16. Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study

ÖZCAN E., KÜÇÜKARDA A., GÖKYER A., Sayin S., GÖKMEN İ., HACIOĞLU M. B., et al.

Journal of Oncological Science , cilt.9, sa.3, ss.134-141, 2023 (Scopus, TRDizin)

17. The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study

Hizal M., Bilgin B., Paksoy N., AÇIKGÖZ Ö., Sezer A., Gürbüz M., et al.

Journal of Cancer Research and Clinical Oncology , cilt.148, sa.6, ss.1501-1508, 2022 (SCI-Expanded, Scopus)

18. Recurrent delayed immune-related pneumonitis after immune-checkpoint inhibitor therapy for advanced osteosarcoma

KÜÇÜKARDA A., GÖKMEN İ., ÖZCAN E., Peker P., AKGÜL F., ÇİÇİN İ.

Immunotherapy , cilt.14, sa.6, ss.395-399, 2022 (SCI-Expanded, Scopus)

19. **Comparison of real-life data from patients with NGS panel negative and KRAS mutation positive metastatic lung adenocarcinoma**

Gokyer A., KÜÇÜKARDA A., KÖSTEK O., Gokmen I., ÖZCAN E., Sayin S., et al.

TUMORI JOURNAL , cilt.108, sa.2, ss.141-146, 2022 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

20. Prognostic nutritional index and its dynamics after curative treatment are independent prognostic factors on survival in non-metastatic nasopharyngeal carcinoma

KÜÇÜKARDA A., ERDOĞAN B., Gökyer A., Sayın S., Gökmen İ., Özcan E., et al.

Supportive Care in Cancer , cilt.30, sa.3, ss.2131-2139, 2022 (SCI-Expanded, Scopus)

21. Breast, ovarian and other site cancer patients with BRCA 1/2 mutations: Data from Turkish multicenter retrospective study

KÖSTEK O., KÜÇÜKARDA A., Tozkir H., Nihat Okten I., Ozden E., ÇABUK D., et al.

Journal of B.U.ON. , cilt.26, sa.6, ss.2654-2661, 2021 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

22. Is early change in systemic inflammatory markers associated with treatment response in patients who received pazopanib?

ERDOĞAN B., KÖSTEK O., HACIOĞLU M. B., GÖKYER A., KÜÇÜKARDA A., ÖZCAN E., et al.

Journal of B.U.ON. , cilt.26, sa.5, ss.2196-2201, 2021 (SCI-Expanded, Scopus)

23. Skeletal muscle loss during anti-epidermal growth factor receptor therapy is an independent prognostic factor on non-small cell lung cancer patients survival

KÜÇÜKARDA A., GÖKYER A., GÖKMEN İ., Bekir Hacioglu M., KÖSTEK O., KURT N., et al.

Journal of B.U.ON. , cilt.26, sa.3, ss.853-860, 2021 (SCI-Expanded, Scopus)

24. Distribution data of epidermal growth factor receptor mutations detected by next-generation sequencing method in non-small cell lung cancer

GÖKMEN İ., TAŞTEKİN E., GÖKYER A., Sayin S., ÇİÇİN İ.

Journal of Oncological Science , cilt.7, sa.2, ss.77-80, 2021 (Scopus, TRDizin)